Profile data is unavailable for this security.
About the company
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
- Revenue in USD (TTM)736.00k
- Net income in USD-62.24m
- Incorporated2005
- Employees59.00
- LocationVistagen Therapeutics Inc343 ALLERTON AVENUESOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 577-3600
- Websitehttps://www.vistagen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lixte Biotechnology Holdings Inc | 0.00 | -4.13m | 17.40m | 2.00 | -- | 7.38 | -- | -- | -1.18 | -1.18 | 0.00 | 0.8612 | 0.00 | -- | -- | 0.00 | -114.55 | -113.03 | -130.06 | -121.30 | -- | -- | -- | -- | -- | -1,017.39 | 0.00 | -- | -- | -- | 29.51 | -- | -- | -- |
| Phio Pharmaceuticals Corp | 0.00 | -7.95m | 17.76m | 5.00 | -- | 0.9701 | -- | -- | -2.73 | -2.73 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -91.57 | -73.65 | -107.58 | -86.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 33.96 | -- | -57.49 | -- |
| Vyne Therapeutics Inc | 524.00k | -33.79m | 18.97m | 13.00 | -- | 0.5644 | -- | 36.21 | -0.7917 | -0.7888 | 0.0123 | 1.01 | 0.0093 | -- | -- | 40,307.69 | -60.16 | -107.54 | -70.67 | -136.47 | -- | -- | -6,448.47 | -1,720.83 | -- | -- | 0.00 | -- | 18.16 | -- | -42.82 | -- | 60.46 | -- |
| Serina Therapeutics Inc | 130.00k | -18.59m | 19.52m | 12.00 | -- | -- | -- | 150.12 | -1.88 | -1.88 | 0.0133 | 0.1669 | 0.0131 | -- | -- | 10,833.33 | -187.74 | -188.54 | -- | -- | -- | -- | -14,331.54 | -7,513.03 | -- | -730.13 | 0.6444 | -- | -60.56 | -49.64 | 24.74 | -- | -49.05 | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -7.98m | 19.54m | 2.00 | -- | 2.48 | -- | -- | -0.1942 | -0.1942 | 0.00 | 0.1932 | 0.00 | -- | -- | 0.00 | -63.16 | -108.15 | -69.69 | -112.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.45 | -- | -- | -- |
| Jupiter Neurosciences Inc | 0.00 | -7.60m | 19.89m | 4.00 | -- | 345.16 | -- | -- | -0.2296 | -0.2296 | 0.00 | 0.0017 | 0.00 | -- | -- | 0.00 | -570.85 | -383.24 | -- | -- | -- | -- | -- | -902.90 | -- | -- | 0.7183 | -- | -- | -- | 49.00 | -- | -- | -- |
| Provectus Biopharmaceuticals Inc | 350.44k | -6.63m | 19.92m | 6.00 | -- | -- | -- | 56.85 | -0.0158 | -0.0158 | 0.0008 | -0.0146 | 0.5736 | -- | -- | 58,406.67 | -1,102.23 | -267.67 | -- | -- | -- | -- | -1,921.64 | -1,092.28 | -- | -27.00 | -- | -- | 10.66 | -- | -52.58 | -- | -- | -- |
| Vistagen Therapeutics Inc | 736.00k | -62.24m | 20.03m | 59.00 | -- | 0.2964 | -- | 27.22 | -1.91 | -1.91 | 0.0227 | 1.71 | 0.008 | -- | -- | 13,142.86 | -67.86 | -55.19 | -76.71 | -59.56 | -- | -- | -8,455.98 | -5,842.62 | -- | -- | 0.0098 | -- | -54.32 | -- | -75.12 | -- | -- | -- |
| Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 20.52m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
| Oncotelic Therapeutics Inc | 0.00 | -1.67m | 20.75m | 26.00 | -- | 2.28 | -- | -- | -0.0041 | -0.0041 | 0.00 | 0.0206 | 0.00 | -- | -- | 0.00 | -7.00 | -20.78 | -19.04 | -43.80 | -- | -- | -- | -1,590.30 | -- | -0.5591 | 0.632 | -- | -100.00 | -- | 42.76 | -- | -- | -- |
| Finch Therapeutics Group Inc | 0.00 | -14.17m | 21.36m | 18.00 | -- | 1.50 | -- | -- | -8.82 | -8.82 | 0.00 | 8.86 | 0.00 | -- | -- | -- | -25.20 | -- | -28.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| NanoViricides, Inc | 0.00 | -8.13m | 21.57m | 7.00 | -- | 2.45 | -- | -- | -0.5115 | -0.5115 | 0.00 | 0.4087 | 0.00 | -- | -- | 0.00 | -80.86 | -43.34 | -94.03 | -45.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.14 | -- | 45.82 | -- |
| Neuphoria Therapeutics Inc | 15.66m | -9.47m | 21.78m | 7.00 | -- | 0.7632 | -- | 1.39 | -3.77 | -3.77 | 8.42 | 5.31 | 0.6233 | -- | 266.10 | 2,237,532.00 | -37.69 | -35.39 | -44.48 | -39.01 | -- | -- | -60.47 | -375.66 | -- | -- | 0.0026 | -- | -- | 246.65 | 97.61 | -- | -- | -- |
| Apollomics Inc | 8.50m | -31.19m | 21.84m | 13.00 | -- | -- | -- | 2.57 | -26.61 | -26.61 | 8.01 | -3.99 | 0.3721 | -- | -- | 653,846.10 | -136.51 | -- | -276.35 | -- | -- | -- | -366.92 | -- | -- | -- | -- | -- | -- | -- | 68.80 | -- | -- | -- |
| Senti Biosciences Inc | 0.00 | -47.58m | 21.87m | 34.00 | -- | 2.69 | -- | -- | -2.80 | -2.80 | 0.00 | 0.3089 | 0.00 | -- | -- | 0.00 | -86.19 | -50.97 | -106.55 | -57.59 | -- | -- | -- | -2,565.78 | -- | -- | 0.00 | -- | -100.00 | -- | 36.71 | -- | -58.03 | -- |
| Polyrizon Ltd | 0.00 | -1.16m | 22.08m | 1.00 | -- | 0.7388 | -- | -- | -582.43 | -582.43 | 0.00 | 18.75 | 0.00 | -- | -- | 0.00 | -11.74 | -80.79 | -12.20 | -179.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.91 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Vistagen Therapeutics Inc's reporting currency: US Dollar USD
32.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 30 Sep 2025 | 4.17m | 10.55% |
| StemPoint Capital LPas of 30 Sep 2025 | 2.49m | 6.30% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.60m | 4.04% |
| Commodore Capital LPas of 30 Sep 2025 | 1.58m | 3.99% |
| OrbiMed Advisors LLCas of 31 Jan 2026 | 808.70k | 2.05% |
| Ikarian Capital LLCas of 30 Sep 2025 | 620.87k | 1.57% |
| Jane Street Capital LLCas of 31 Dec 2025 | 527.13k | 1.34% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 416.83k | 1.06% |
| Geode Capital Management LLCas of 31 Dec 2025 | 352.84k | 0.89% |
| Diadema Partners LPas of 30 Sep 2025 | 349.79k | 0.89% |
More ▼
Data from 30 Sep 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
